Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H23N3O7S |
Molecular Weight | 461.488 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)OCC4=C(C)OC(=O)O4
InChI
InChIKey=ZKUKMWMSYCIYRD-ZXFNITATSA-N
InChI=1S/C21H23N3O7S/c1-10-12(31-20(28)30-10)9-29-19(27)15-21(2,3)32-18-14(17(26)24(15)18)23-16(25)13(22)11-7-5-4-6-8-11/h4-8,13-15,18H,9,22H2,1-3H3,(H,23,25)/t13-,14-,15+,18-/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/4053214
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4053214
Lenampicillin is a prodrug of ampicillin that inhibits bacterial penicillin binding proteins (transpeptidase) and thus is effective against a wide range of bacterial infections. The drug was developed and marketed in Japan (Takacillin, Varacillin), however its current marketing status is unknown and supposed to be discontinued.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2683579 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | TAKACILLIN Approved UseVarious infections including respiratory, urinary tract, skin and soft tissue, surgical, otolaryngological, ophthalmological and dental infections due to susceptible microorganism |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3906167
1,000 mg, in 4 equally divided doses
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1500
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5467
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
86273-18-9
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
DTXSID1057901
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106329
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
65646
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
C90912
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
100000082588
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
m6761
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
C045384
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
1553
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
SUB08430MIG
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
8M568DM08K
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
135748
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)